Compare RXO & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RXO | EWTX |
|---|---|---|
| Founded | 2022 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.3B |
| IPO Year | 2022 | 2021 |
| Metric | RXO | EWTX |
|---|---|---|
| Price | $28.45 | $40.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 13 |
| Target Price | $29.83 | ★ $56.17 |
| AVG Volume (30 Days) | ★ 3.4M | 1.4M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.81 | N/A |
| EPS | N/A | ★ 8.86 |
| Revenue | ★ $5,742,000,000.00 | N/A |
| Revenue This Year | $21.30 | N/A |
| Revenue Next Year | $10.66 | N/A |
| P/E Ratio | ★ N/A | $4.65 |
| Revenue Growth | ★ 26.20 | N/A |
| 52 Week Low | $11.18 | $19.76 |
| 52 Week High | $29.90 | $48.78 |
| Indicator | RXO | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.68 | 44.25 |
| Support Level | $28.14 | $37.22 |
| Resistance Level | $28.68 | $41.60 |
| Average True Range (ATR) | 0.43 | 3.20 |
| MACD | -0.13 | -0.37 |
| Stochastic Oscillator | 63.48 | 26.45 |
RXO Inc is a brokered transportation platform defined by technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.